1. In Vivo
  2. >>Innovation

Big Pharma Holds Steady With One-Third Of Novel Agents Approved In US In 2020

 
• By Bridget Silverman

Gilead and Roche ended the year involved in three novel agents apiece, thanks to a combination of internal research and external licensing.

blocks
HOW DO THE BIGGEST FIRMS STACK UP IN NOVEL APPROVALS?

Big pharma companies sponsored about one in three of the US Food and Drug Administration’s 58 novel approvals in 2020, marking the fifth year in a row that the largest firms claimed around one-third of new molecular entities and novel biologics.

The big pharma share has stayed stable despite approval counts ranging from record-breaking highs – 2020 is second only to the contemporary FDA approvals peak in 2018 – to the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.